CellRapeutics™ CAR-T Engineering Strategies for In Vivo Imaging Detection Service

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The Potential of CAR-T Imaging for Cancer Immunotherapy

CAR-T immunotherapy is a robust treatment strategy for hematologic malignancies with dramatic anti-tumor efficacy. However, the expansion and trafficking rate of CAR-T cells are often insufficient to produce long-term remission, and serious CRS toxicities may occur after administration. The imaging platform development for CAR-T cell expansion and trafficking visualization will provide a promising approach to monitor inadequate response and act as an early warning for CAR-T toxicity, allowing CAR-T therapy to be tailored accordingly to maximize therapeutic efficiency.

Fig.1 The schematic of in vivo CAR-T imaging.¹

Our CellRapeutics™ CAR-T Engineering Strategies for In Vivo Imaging Detection Service

To this end, Creative Biolabs is committed to providing comprehensive CAR-T imaging services for global customers to facilitate the tracking of CAR-T cells in vivo. Our services cover non-specific strategies to visualize activated T cells and robust reporter systems to specifically monitor engineered T cells. These approaches are expected to provide valuable information and guidance to improve CAR-T therapy.

The Breadth of Our CAR-T Imaging Service

Our CAR-T imaging services cover a variety of non-specific approaches to detect activated T cells, and many robust reporter systems to specifically monitor engineered T cells, including but not limited to the following sections:

Non-specific CAR-T Imaging Service of Activated T cells:

In vivo activated T cell imaging utilizing surface activation markers:
CD25, OX40, PD-1, CTLA-4, Granzyme B, IFN-γ;

In vivo activated T cell imaging utilizing metabolic pathways kinase:
Deoxycytidine kinase (dCK), Deoxyguanosine kinase (dGK);

In vivo activated T cell imaging utilizing T cell-specific surface markers:
TCR, CD3, CD4, CD8;

Specific CAR-T Imaging Service using Reporter Genes:

Herpes simplex virus 1 thymidine kinase (HSV-tk);

Sodium iodide symporter (NIS);

Somatostatin receptor type 2 (SSTr2);

Human deoxycytidine kinase (hdCK);

What the Data Say

In vivo CAR-T imaging with nanoparticle labeling

Fig.2 Photoacoustic images of CAR-T cells visualization labeled with ferumoxytol.²

Frequently Asked Questions

Q1: What is the significance of CAR-T imaging development?

A1: As CAR-T therapy continues to become an important means of cancer treatment, there will be an urgent need to develop several appropriate imaging platforms to allow non-invasive imaging and monitoring of the expansion and trafficking rate of CAR-T cells in vivo. CAR-T cell dynamics visualization is of great significance in studying the interaction between T cells and cancer cells, as well as several normal tissues.

Q2: What criteria should an ideal CAR-T imaging platform meet?

A2: Such a CAR-T imaging platform meets the following criteria:

The reporter/molecule in the imaging platform should be non-immunogenic;
When detecting the low quantity of CAR-T cells, the platform should have high sensitivity to image;
The reporter/molecule of the imaging platform should have low background expression on normal tissue;
The imaging molecular and imaging process should not affect abnormal CAR-T cell functions.

Work with Creative Biolabs

Creative Biolabs provides comprehensive in vivo CAR-T imaging services that allow for full customization and design from pilot studies to special targeted projects. If you are interested in more information about our in vivo CAR-T imaging service, please don't hesitate to contact us.

References

Sakemura, R.; et al. In vivo CAR-T cell imaging: Paving the way for success in CAR-T cell therapy. Mol Ther Oncolytics. 2021, 20:625-633.
Kiru, L.; et al. In vivo imaging of nanoparticle-labeled CAR-T cells. Proc Natl Acad Sci U S A. 2022, 119(6):e2102363119.